


Botulinum Toxin Type A vs. Placebo for Idiopathic Clubfoot



Congenital idiopathic clubfoot affects 1/1,000 infants

In a double-blind, parallel-group study infants treated with Ponseti method until the lack of progression of ankle dorsiflexion (or hindfoot stall) were...

Botulinum toxin A (BTX-A)



n = 32



Placebo




n = 30

Outcomes:

Primary: Proportion of responders (achievement of $\geq 15^\circ$ ankle dorsiflexion) at 2 years of age (T3)

Secondary: Proportion of responders at 6 (T1) and 12 (T2) weeks

Patient outcomes following BTX-A or placebo injections for hindfoot stall



92% of the clubfeet responded to treatment by 2 years of age

No differences were noted in outcomes between the botulinum toxin A and placebo groups after injections for hindfoot stall

Botulinum Toxin Type A Versus Placebo for Idiopathic Clubfoot
A Two-Center, Double-Blind, Randomized Controlled Trial

Alvarez et al. (2018)

DOI: 10.2106/JBJS.17.01652

www.jbjs.org

theJBJS

@JBJS

